Previous studies have reported that phosphodiesterase 10A (PDE10) is overexpressed in colon epithelium during early stages of colon tumorigenesis and essential for colon cancer cell growth. Here we describe a novel non-COX inhibitory derivative of the anti-inflammatory drug, sulindac, with selective PDE10 inhibitory activity, ADT 061. ADT 061 potently inhibited the growth of colon cancer cells expressing high levels of PDE10, but not normal colonocytes that do not express PDE10. The concentration range by which ADT 061 inhibited colon cancer cell growth was identical to concentrations that inhibit recombinant PDE10. ADT 061 inhibited PDE10 by a competitive mechanism and did not affect the activity of other PDE isozymes at concentrations that inhibit colon cancer cell growth. Treatment of colon cancer cells with ADT 061 activated cGMP/PKG signaling, induced phosphorylation of oncogenic β-catenin, inhibited Wnt-induced nuclear translocation of β-catenin, and suppressed TCF/LEF transcription at concentrations that inhibit cancer cell growth. Oral administration of ADT 061 resulted in high concentrations in the colon mucosa and significantly suppressed the formation of colon adenomas in the Apc+/min-FCCC mouse model of colorectal cancer without discernable toxicity. These results support the development of ADT 061 for the treatment or prevention of adenomas in individuals at risk of developing colorectal cancer.

Prevention Relevance:

PDE10 is overexpressed in colon tumors whereby inhibition activates cGMP/PKG signaling and suppresses Wnt/β-catenin transcription to selectively induce apoptosis of colon cancer cells. ADT 061 is a novel PDE10 inhibitor that shows promising cancer chemopreventive activity and tolerance in a mouse model of colon cancer.

Nonsteroidal anti-inflammatory drugs (NSAID) inhibit tumorigenesis in a variety of preclinical rodent models of colorectal cancer, but long-term use in humans to treat or prevent colorectal cancer is not recommended because of potentially fatal gastrointestinal, renal, and cardiovascular toxicities resulting from COX inhibition and the suppression of physiologically important prostaglandins (1). Multiple lines of evidence suggest that the mechanism for the antineoplastic activity of NSAIDs may involve targets other than, or in addition to COX (2, 3). For example, doses of NSAIDs exceeding those needed to inhibit COX isozymes, COX-1 or COX-2, are generally required to suppress tumorigenesis in experimental animal models (4, 5). In addition, there is no apparent correlation between potency to inhibit COX and cancer cell growth among several different chemical classes of NSAIDs (6). As a nonselective COX-1/-2 inhibitor, sulindac is considered to be the most effective NSAID to inhibit adenoma formation in patients with familial adenomatous polyposis (FAP) (7–9), possibly because of high concentrations in the intestinal lumen from enterohepatic recirculation, and is among the most potent NSAIDs to inhibit cancer cell growth in vitro (10–12). Sulindac is a prodrug that requires reductive metabolism by colonic bacteria to convert it from a sulfoxide to sulindac sulfide (SS), which is the active form of the drug that inhibits COX-1 and COX-2 (13). The sulfoxide is also oxidized in the liver to a sulfone that does not inhibit COX-1 or COX-2. Despite lacking COX inhibitory activity, sulindac sulfone inhibits cancer cell growth in vitro at concentrations only slightly higher than sulindac sulfide (10, 11). Sulindac sulfone exhibited protective activity in multiple rodent models of colon tumorigenesis without affecting colonic prostaglandin levels (14, 15). Lacking toxicities associated with COX inhibition, sulindac sulfone (exisulind) was evaluated in clinical trials for its ability to inhibit adenoma formation in individuals with FAP or sporadic polyposis, but was found to be only moderately effective, most likely due to low potency and dose-limiting hepatotoxicity (16–19).

Previous studies suggest that the antineoplastic activity of sulindac and exisulind is associated with cyclic guanosine monophosphate (cGMP) phosphodiesterase (PDE) inhibition. Both drugs inhibit cancer cell growth at concentrations comparable with those that inhibit the cGMP PDE activity of cell lysates or recombinant PDE isozymes (6, 17, 18, 20–22). In addition, certain non-COX inhibitory derivatives were synthesized that exhibit appreciably greater potency to inhibit cancer cell growth and cGMP PDE activity (18, 22). However, it was unclear which cGMP degrading PDE isozyme(s) is responsible for the anticancer activity of sulindac or exisulind, as neither displayed significant selectivity for any specific GMP degrading PDE isozyme (17, 18).

Eleven distinct families of PDE isozymes have been identified that comprise over 100 different isoforms or splice variants (23). PDE5, 6, and 9 selectively hydrolyze cGMP, while PDE4, 7, and 8 selectively hydrolyze cyclic adenosine monophosphate (cAMP). PDE1, 2, 3, 10, and 11 hydrolyze both cAMP and cGMP (24). Previous studies suggest that the PDE10 isozyme is unique from other PDE isozymes because of high expression in cancer cells relative to cells from normal tissues (22, 25–27). In addition, PDE10 was found to be elevated in colon adenomas and adenocarcinomas relative to normal colonic mucosa (25, 27). An important role of PDE10 in tumorigenesis is suggested by experiments showing that PDE10 knockdown by genetic silencing or inhibition of enzymatic activity with highly specific small molecule inhibitors suppress the growth of cancer cells expressing PDE10, but not cells derived from normal tissues with low PDE10 expression (25–27).

Here we describe a novel PDE10 inhibitor, ADT 061, that was identified by synthesis and screening of a large custom library of indenes chemically related to sulindac but lacking COX inhibitory activity. ADT 061 potently and selectivity inhibited colon cancer cell growth, increased cyclic nucleotide levels, and activated cGMP-dependent protein kinase (PKG) at concentrations that inhibit recombinant PDE10. Activation of cGMP/PKG signaling in colon cancer cells by ADT 061 induced the phosphorylation of β-catenin and suppressed nuclear levels of β-catenin and TCF/LEF transcriptional activity. Oral administration of ADT 061 resulted in high local concentrations in the colonic mucosa and significantly inhibited adenoma formation without discernable toxicity in a mutant Apc mouse model of colon tumorigenesis.

Chemical synthesis

The synthesis of ADT 061 [(Z)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(pyridin-3-yl) acetamide] is based on a procedure originally described in U.S. patent 6,063,818 as “Example 1” (28). The synthesis used 4-methoxy-benzaldehyde (Sigma-Aldrich) as the starting material and involved multiple reaction steps (a–f) with five key intermediates (1–5) as illustrated in Supplementary Figs. S1–S4 and described in detail in the figure legend.

Cell culture

Human HT-29, HCT 116, SW480, and Caco2 colon carcinoma cells were purchased from the ATCC (HTB-38, CCL-247, CCL-228, and HTB-37, respectively) and cultured according to the manufacturer's recommendations. Cancer cell line identity was confirmed by short tandem repeat profiling at LabCorp (Genetica). Cells were maintained in culture for 20 passages or less, and tested regularly to ensure absence of Mycoplasma contamination. The human normal colonic mucosal epithelial cell line, NCM460, was purchased from INCELL Corporation, LLC, and grown according to the manufacturer's recommendations, and maintained in culture for less than 12 passages (29). Cell growth inhibition assays were performed as described previously (26, 27). PDE10 siRNA knockdown cells were generated previously (25).

PDE assays

PDE assays were performed using recombinant PDE isozymes (BPS Bioscience) in conjunction with the IMAP FP Screening Express Kit (Molecular Devices Inc,), as described previously (27). To determine enzyme kinetics, the concentrations of enzyme, ADT 061, and fluorescently labeled cyclic nucleotide were held constant, while unlabeled cyclic nucleotides were added in increasing concentrations to the reaction. The PDE10 specific inhibitor, Pf2545920 (Selleck Chemicals, LLC), served as a positive control for assessing PDE10 inhibitory activity of ADT 061.

PDE10 immunoprecipitation

Cell lysates were incubated with 10 μL of Protein A agarose beads (Cell Signaling Technology) per 100 μL of lysate for 30 minutes on a rotator at 4°C. Lysates were spun at 6,000 rpm for 10 minutes and beads discarded. PDE10 antibody (C2C3, Genetex, Inc.) and IgG control (Cell Signaling Technology) were incubated overnight at 4°C on a rotator. Protein A agarose beads were added and incubated for 1 hour on a rotator at 4°C, centrifuged and the supernatant discarded. Beads were washed in lysis buffer and prepared for Western blot analysis. For the PDE assay, an additional wash was performed in PDE reaction buffer (Molecular Devices) and enzymatic activity was measured by fluorescence polarization using a Biotek Synergy H4 plate reader.

COX inhibition

COX inhibition was determined using the COX Fluorescent Inhibitor Screening Assay Kit (Cayman Chemical) according to the manufacturer's recommendation. SS (Sigma-Aldrich; 10 μmol/L) served as a positive control for assessing the COX-1 and COX-2 inhibitory activity of ADT 061. Celecoxib (Selleck Chemicals; 100 nmol/L) and indomethacin (Sigma-Aldrich; 100 nmol/L) served as additional controls as COX-2 and COX-1 specific inhibitors, respectively. The protocol was modified to include a 20-minute incubation step prior to the addition of arachidonic acid. Fluorescent readings were obtained using a Biotek Synergy H4 plate reader.

Intracellular cyclic nucleotide measurements

Intracellular cyclic nucleotide concentrations were assayed using Cyclic GMP/AMP ELISA Kits (Cayman Chemical) according to the manufacturer's recommendations and as described previously (27).

Western blot analysis

Western blots were performed as described previously (27). All antibodies were purchased from Cell Signaling Technology except PDE10 (C2C3, Genetex, Inc. GTX118886), total β-catenin (Clone 14, BD Biosciences 610153), and β-actin (Sigma-Aldrich A1978). Cell Signaling antibodies are as follows: p-VASP Ser239 (Cell Signaling Technology, 3114), p-VASP Ser157 (Cell Signaling Technology, 3111), VASP (Cell Signaling Technology, 3132), p-β-catenin Ser33/37/Thr41 (Cell Signaling Technology, 9561), β-catenin Ser552 (Cell Signaling Technology, 5651), Survivin (Cell Signaling Technology, 2808), Cl Caspase-3 (Cell Signaling Technology, 9664), p-CREB (Cell Signaling Technology, 9198), GAPDH (Cell Signaling Technology, 5174).

Luciferase reporter

TCF/LEF transcriptional activity was determined as described previously (22).

Confocal immunofluorescence microscopy

Fluorescent images were acquired using a Nikon A1 Laser Scanning Confocal microscope. SW480 cells were analyzed for nuclear translocation of β-catenin following Wnt stimulation as described previously (27). Samples were co-stained with antibodies against total β-catenin (Clone 14, BD Biosciences) and non-phospho serine 45-β-catenin (D2U8Y, Cell Signaling Technology, 19807) before counterstaining with Alexa-Fluor 488 and 647, respectively. For quantification, the region of interest generator in Nikon Elements was used to automatically select nuclei positive for DAPI staining. Staining intensity was then exported for each channel of interest on a minimum of 100 cells per treatment. Hyperspectral imaging coupled with linear unmixing was performed to determine the localization of PDE10 in colon tissue. Spectral imaging and analysis was used to separate the autofluorescence signal from the AlexaFluor-488 labeling of PDE10, as described previously (30, 31). A library containing pure spectra of AlexaFluor-488 (PDE10), AlexaFluor-647 (β-catenin), and DAPI (nuclei) was constructed using single labeled controls of HT-29 cells labeled with only AlexaFluor-488, AlexaFluor-647, and DAPI, respectively. Normal colon tissue section was used to obtain the autofluorescence spectral signature. Images were scaled similarly and false colored for visualization as indicated in the text.

Plasma and tissue concentrations of ADT 061 after oral administration

ADT 061 oral bioavailability was evaluated using 7–8 weeks old, female C57BL/6 mice. ADT 061 was administered at a dosage of 100 mg/kg by oral gavage once as a suspension in 0.5% carboxymethyl cellulose/0.25% tween 80 (T80) in sterile water. Each mouse had blood collected twice: the first timepoint was a survival bleed (0.5, 1, or 4 hours after administration) and the second timepoint was a terminal bleed (2, 8, or 24 hours after administration). There were 4 mice per timepoint. Blood was processed for plasma and frozen. In addition to blood collection, lungs, colonic mucosa, ovaries, uterus, and brain were collected 2, 8, or 24 hours after treatment and frozen. Drug levels were measured using LC/MS-MS methodology. Results were presented as mean ± SD. This study was approved by the Institutional Animal Care and Use Committee of the University of South Alabama (protocol #755414).

LC/MS-MS analysis

Mouse tissue samples were homogenized either 1:5 or 1:10 with 5 mmol/L ammonium acetate buffer using an Omni THQ homogenizer. Calibration standards, blanks and quality control samples (QCs) were prepared by spiking naïve mouse plasma or tissue homogenate (50 μL) with the appropriate amount of ADT 061 to achieve concentrations in tissue homogenate or plasma ranging from 5–10,000 ng/mL standards, blanks, QCs and samples were spiked with internal standard (500 μL of 10 ng/mL terfenadine in acetonitrile) and vortexed for 10 seconds to precipitate the proteins. After centrifugation for 5 minutes at 21,000 × g, the supernatant was removed and transferred to an autosampler vials and analyzed in positive ion mode by LC/MS-MS. The LC/MS-MS system consisted of Shimadzu Prominence system equipped with LC20-AD dual HLPC pumps, an SIL20-AC HT autosampler, and a DGU-20A2 in-line degasser. Detection was performed using an Applied BioSystems 4000 QTRAP (Applied Biosystems) triple quadrupole mass spectrometer operated in the positive ion mode. Mass calibration, data acqusition, and quantitaion were performed using Applied Biosystem Analyst 1.6.2 software (Applied Biosystems). Separation of the ADT 061 and the internal standard from the plasma or homogenate matrix was achieved using a Phenomenex Luna C18, 100×2 mm 5 μm particle column equipped with a C18 Security Guard cartridge (Phenomenex). The mobile phase was delivered at a flow rate of 400 μL/minute using a gradient elution profile consisting of deionized (DI) water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). ADT 061 was analyzed using an elution profile in which mobile phase B was held at 20% for 1 minute, then increased linearly to 90% over 5 minutes, held at 90% for 1.5 minutes, returned to 20% and equilibrated for 2.5 minutes. The analyte and internal standard were detected after a 10 μL injection using multiple reaction monitoring for the following the following transitions: ADT 061 (m/z 473.3.4→121.0), Terfenadine (m/z 472.4→ 436.3).

Liver enzyme analysis

Male Apc+/Min-FCCC mice (6–8 weeks of age, N = 40) were randomized to treatment groups and treated for 6 weeks. The activity of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) was measured in plasma samples collected at necropsy (n = 9/group) using commercial ELISA kits, according to manufacturer's instructions (Biovision). This study was approved by the Institutional Animal Care and Use Committee of Fox Chase Cancer Center (protocol #14-07).

Evaluation of antitumor activity

A colony of Apc+/Min-FCCC mice has been established at Fox Chase Cancer Center (FCCC, Philadelphia, PA) and maintained for over 80 generations (32). Because male APC+/Min-FCCC mice develop twice as many colon adenomas and have a higher incidence of colon tumors than femail APC+/Min-FCCC mice, only male mice were used in the current study. Mice were maintained on a Harlan Teklad 2018SX diet (Envigo) and had access to food and water ad libitum. Prior to ADT 061 treatment, colonoscopies were performed on all Apc+/Min-FCCC mice (ref. 33; 6–7 weeks of age) to ensure the absence of colorectal adenomas. At 7 to 8 weeks of age, mice were assigned to groups of 19–21 mice receiving either unsupplemented chow (control), or chow supplemented with either 1,000 or 1,500 ppm ADT 061 for 14 weeks. Body weights were recorded weekly. At the time of euthanasia, the entire intestine was examined grossly, fixed in 10% buffered formalin, and submitted for histopathologic review. This study was approved by the Institutional Animal Care and Use Committee of FCCC (Philadephia, PA; protocol #14-07).

Histopathology

Formalin-fixed paraffin-embedded (FFPE) tissues were sectioned, stained with hematoxylin and eosin, and reviewed in a blinded manner by a gastrointestinal pathologist with extensive experience with the Apc+/Min-FCCC mouse model. Tumors were classified as adenomas (>4 dysplastic crypts) or microadenomas (1–4 dysplastic crypts). Adenomas were further categorized as polypoid or flat. Polypoid adenomas projected above the mucosa, while flat adenomas were less than twice the height of the adjacent normal mucosa. This definition is consistent with the criteria for adenomas established by a leading panel of intestinal pathologists (34).

Statistical analysis

Growth assays as well as all enzymatic assays (PDE and COX) were performed with a minimum of three replicates and repeated at least twice. All Western blots and immunofluorescence experiments were repeated with at least two biological replicates. Statistical analysis was performed using GraphPad Prism software using ANOVA for two or more groups. Statistical comparisons of colon tumor data were performed using Fisher exact test for tumor incidence and the Wilcoxon test for tumor multiplicity.

COX-independent cancer cell growth inhibitory activity of ADT 061

ADT 061 contains the same indene scaffold as sulindac but with several chemical modifications (Fig. 1A) aimed at blocking COX binding to reduce toxicity while improving potency and selectivity to inhibit PDE10 that we hypothesized could enhance anticancer efficacy. SS nonselectively inhibited COX-1 and COX-2 by 68%–70% at a concentration of 10 μmol/L, while ADT 061 completely lacked COX-1 or COX-2 inhibitory activity at concentrations up to 50 μmol/L (Fig. 1B). As controls, the COX-1 inhibitor, indomethacin, selectively inhibited COX-1, while the COX-2 inhibitor, celecoxib selectively inhibited COX-2. Despite lacking COX inhibitory activity, ADT 061 potently inhibited the growth of colon cancer cell lines, HCT116, HT-29, and SW480, with IC50 values of 0.31, 0.33, and 0.37 μmol/L, respectively, but did not appreciably affect the growth of normal colon mucosal (NCM460) cells grown under similar conditions at concentrations up to 50 μmol/L (Fig. 1C). SS was appreciably less potent than ADT 061 to inhibit the growth of colon cancer cells with IC50 values 110-fold to190-fold higher and was also less selective for cancer cells as compared with NCM460 cells (Fig. 1D). PDE10 was expressed in all colon cancer cell lines examined but was essentially undetectable in NCM460 cells (Fig. 1E) as published previously (25).

ADT 061 selectively inhibits PDE10

The PDE isozyme selectivity of ADT 061 was determined using recombinant PDE isozymes, PDE1–11, with cAMP and/or cGMP as substrates based on the known substrate specificity of each PDE isozyme. At a concentration of 1 μmol/L, ADT 061 inhibited PDE10 by 75% and 50% with cGMP and cAMP as a substrate, respectively, without appreciably affecting the activity of all other PDE isozymes (Fig. 2A). Testing a wide range of concentrations revealed that ADT 061 inhibited recombinant PDE10 using cGMP as a substrate with an IC50 of 0.3 μmol/L. Slightly higher concentrations of ADT 061 were required to inhibit PDE10 when cAMP was used as the substrate with an IC50 of 1.0 μmol/L (Fig. 2B). By comparison, SS inhibited PDE10 with an IC50 of 70 μmol/L that was comparable with its potency to inhibit cancer cell growth but was not isozyme selective as reported previously (22).

Experiments were also conducted to determine whether ADT 061 binds PDE10 in a competitive manner by measuring the enzymatic activity of recombinant PDE10 in the presence of varying cGMP concentrations. As calculated by Michaelis-Menten kinetics, ADT 061 increased the Km of PDE10 for cGMP to reach half maximal velocity from 5.4 to 17.9 μmol/L, while not significantly affecting maximal velocity (Vmax; Fig. 2C). The competitive nature by which ADT 061 inhibits PDE10 was also apparent using the Eadie–Hofstee method by plotting velocity as a function of velocity/substrate concentration showing non-parallel intersecting lines for ADT 061 versus control (Supplementary Fig. S5).

To further determine whether PDE10 inhibition is responsible for the cancer cell growth inhibitory activity of ADT 061, PDE10 levels were suppressed in HT-29 cells by siRNA knockdown. This resulted in reduced sensitivity to ADT 061 from an IC50 of 0.32 μmol/L in vector control cells to 1.9 μmol/L in PDE10 knockdown cells (Fig. 2D). The activity of ADT 061 remaining despite treatment was likely attributed to incomplete knockdown of PDE10. In addition, the sensitivity of PDE10, extracted from HT-29 cells by immunoprecipitation, to ADT 061 was determined to be comparable to that of recombinant PDE10 (Fig. 2E).

ADT 061 activates cGMP/PKG signaling

As predicted for a PDE10 inhibitor, treatment of HT-29 colon cancer cells with ADT 061 significantly increased both intracellular cGMP and cAMP levels at concentrations that inhibited cancer cell growth (Fig. 3A). To determine whether the magnitude of the effect of ADT 061 treatment on elevating intracellular cGMP and/or cAMP levels was sufficient to induce downstream signaling, PKG and PKA activity were measured by Western blot analysis using phospho-specific antibodies against VASP and CREB. VASP is phosphorylated preferentially by PKG on Ser239 and by PKA on Ser157 residues (25, 27, 35, 36). ADT 061 at a concentration of 0.3 μmol/L increased Ser239 phosphorylation within 30 minutes of treatment without affecting the phosphorylation of VASP at Ser157 (Fig. 3B). Testing a wider range of concentrations confirmed that ADT 061 increased Ser239 phosphorylation at concentrations effective for inhibiting colon cancer cell growth, while appreciably higher concentrations were required to increase Ser157 phosphorylation (Fig. 3C). In addition, ADT 061 did not induce CREB phosphorylation at Ser133, which is exclusively phosphorylated by PKA (37). These results suggest that the increase in intracellular cGMP levels by ADT 061 treatment is sufficient to activate PKG and inhibit colon cancer cell growth, while the increase in cAMP levels is insufficient to activate PKA and inhibit growth.

ADT 061 reduces oncogenic β-catenin

Previous studies have reported that PKG can phosphorylate β-catenin to induce proteasomal degradation of β-catenin (24, 26, 38). To determine whether PDE10 inhibition and activation of cGMP/PKG signaling by ADT 061 can phosphorylate and reduce levels of β-catenin, HT-29, and SW480 colon cancer cells were treated with ADT 061 at concentrations that inhibit colon cancer cell growth and extracts were probed by Western blot analysis using phospho-specific antibodies against specific β-catenin residues. ADT 061 treatment reduced the non-phosphorylated (stable) form of β-catenin at Ser45, which represents a reduction of the oncogenic pool of β-catenin (Fig. 3D). Conversely, ADT 061 treatment increased levels of phosphorylated β-catenin at Ser33, 37/Thr41 residues, which are known to induce ubiquitination and proteasomal degradation of β-catenin (24). Consistent with a mechanism involving the activation of cGMP/PKG signaling, ADT 061 treatment caused an increase in phosphorylation of β-catenin at Ser552, a residue known to be phosphorylated by PKG (26). ADT 061 treatment of HT-29 and SW480 colon cancer cells also reduced levels of survivin (Fig. 3F), a protein that is regulated by TCF/LEF transcription and essential for cancer cell proliferation and survival (39). This effect occurred within the same concentration range of ADT 061 that was effective for inducing apoptosis as detected by increased levels of cleaved caspase 3. ADT 061 treatment of HCT 116 colon cancer cells also reduced the activity of the TCF/LEF transcription factor (Fig. 3E). These effects occurred within the same concentration range of ADT 061 that activated cGMP/PKG signaling in colon cancer cells and inhibited the growth of colon cancer cells.

ADT 061 blocks Wnt-induced nuclear translocation of β-catenin

The effect of ADT 061 on Wnt-induced nuclear translocation of β-catenin was determined in SW480 colon cancer cells harboring mutant APC using Wnt-conditioned media as described previously (27, 40). Confocal immunofluorescence microscopy, utilizing antibodies against total β-catenin and its non-phosphorylated (stable, oncogenic) form at Ser45, revealed that Wnt-conditioned media stimulated nuclear translocation of β-catenin, while control media failed to induce nuclear accumulation of β-catenin (Fig. 4A). Nuclear translocation of β-catenin was confirmed by co-staining cells with antibodies against total and oncogenic β-catenin along with the nuclear marker, DAPI (Fig. 4B). Treatment with ADT 061 at a concentration of 0.5 μmol/L completely blocked Wnt-induced β-catenin translocation to the nucleus (Fig. 4C). Nuclear localization of β-catenin was quantified for total (Fig. 4D) as well as active oncogenic non-phosphorylated forms (Fig. 4E). While staining intensity for total β-catenin did not differ significantly among the treatment groups, the staining intensity for non-phosphorylated active β-catenin increased significantly over control with Wnt stimulation. The effect of Wnt stimulation was completely inhibited by ADT 061.

PDE10 overexpression in the Apc+/Min-FCCC mouse model

Consistent with the overexpression of PDE10 mRNA and protein levels during early stages of colon tumorigenesis as reported previously (25), levels of PDE10 protein were found to be elevated in colon adenomas, as well as in adjacent uninvolved mucosa of Apc+/Min-FCCC mice relative to normal colon mucosa from wildtype (WT) mice when measured by Western blot analysis (Fig. 5A). While PDE10 levels were not appreciably different in uninvolved mucosa and adenomas, cGMP levels as measured by ELISA were significantly reduced in adenomas compared with uninvolved mucosa, suggesting that the enzymatic activity of PDE10 is higher in adenomas relative to uninvolved mucosa (Fig. 5B), despite comparable levels of PDE10 protein (Fig. 5A). Detection of PDE10 in FFPE colon tissue from Apc+/min-FCCC mice by immunolabeling confirmed high levels of PDE10 expression in dysplastic regions (Fig. 5C, red label) that co-localized (white arrows) with β-catenin (Fig. 5C, green label).

ADT 061 inhibits colon adenomas in the Apc+/Min-FCCC mouse model

Pharmacokinetic analysis in mice following a single oral dose of ADT 061 (100 mg/kg) resulted in plasma levels (Cmax = 4.9 μmol/L) that exceeded growth IC50 values by greater than 10-fold for at least 8 hours following administration with a biphasic profile indicative of enterohepatic recirculation (Supplementary Fig. S6). Measurement of ADT 061 levels in various tissues revealed that ADT 061 achieved high levels in colon mucosa (Cmax = 62.6 nmol/g) that were greater than 10- and 30-fold higher relative to levels in plasma and other tissues (Cmax = 1–2 nmol/g), respectively. Unlike known PDE10 inhibitors that achieve high concentrations in the brain and have associated side effects (e.g., sedation), oral administration of ADT 061 resulted in nearly undetectable (0.1 and 0.2 nmol/g) levels in the brain and did not cause sedation.

ADT 061 was evaluated for its ability to inhibit the formation of colon adenomas in Apc+/Min-FCCC mice. Mice used for this study were identified as tumor free by colonoscopy prior to treatment. After 14 weeks of treatment with control (unsupplemented) chow or chow supplemented with either 1,000 or 1,500 ppm ADT 061, no significant difference in body weights was observed between control and treatment groups (Fig. 6A). A dose of 1,500 ppm yielded plasma levels of 0.5 μmol/L, exceeding colon tumor cell growth inhibition IC50 values (0.3 μmol/L) in cell culture (see Fig. 2D). Of note, no hepatotoxicity was observed in an independent study when Apc+/Min-FCCC mice were fed chow supplemented with higher doses of ADT 061 (up to 2,400 ppm). Circulating levels of AST and ALT, biomarkers for liver damage, were unremarkable in mice treated with ADT 061 even at doses higher than those used in the current study (Supplementary Fig. S7).

The activity of ADT 061 against colon tumorigenesis was dose dependent. Treatment of Apc+/Min-FCCC mice with ADT 061 reduced the incidence of colon adenomas by 18.6% at 1,000 ppm (P = 0.186) and 36.9% at 1,500 ppm (P = 0.019; Fig. 6B). The multiplicity of total adenomas (sum of flat, polypoid, and microadenomas) was reduced 27.5% in mice treated with 1,000 ppm ADT 061 (P = 0.31) and 51.3% in mice treated with 1,500 ppm ADT 061 (P = 0.028; Fig. 6C). The multiplicity of adenomas (> 4 dysplastic crypts) was reduced 31.2% in mice treated with 1,000 ppm ADT 061 (P = 0.11) and 46.0% in mice treated with 1,500 ppm ADT 061 (P = 0.026; Fig. 6D). Although not statistically significant, the multiplicity of microadenomas (≤ 4 crypts) was also decreased in mice treated with 1,500 ppm ADT 061 (Fig. 6E). These data indicated that the higher dose of ADT 061 was needed to inhibit colon tumorigenesis in Apc+/Min-FCCC mice.

The results from the present study demonstrate that ADT 061 significantly inhibits colon tumorigenesis when administered orally to Apc+/Min-FCCC mice without discernable toxicity. The mechanism, as studied using colon cancer cells, appears to involve direct inhibition of neoplastic cell growth by targeting PDE10, a PDE isozyme recently found to be overexpressed during early stages of colon tumorigenesis and essential for the proliferation and survival of cancer cells (22, 25, 27). Consistent with a mechanism involving PDE10 inhibition, ADT 061 increased intracellular cyclic nucleotide levels and activated PKG at concentrations that inhibit recombinant PDE10 and cancer cell growth in vitro. ADT 061 activation of cGMP/PKG signaling was associated with reduced levels of the oncogenic pool of β-catenin and the suppression of TCF/LEF transcriptional activity.

As further evidence that PDE10 inhibition is responsible for the cancer cell growth inhibitory activity of ADT 061, siRNA knockdown of PDE10 in colon cancer cells reduced sensitivity to ADT 061 in growth assays. ADT 061 also inhibited the activity of PDE10 extracted from colon cancer cells with an IC50 value achieved when using recombinant PDE10. In addition, treatment of colon cancer cells with ADT 061 increased both cAMP and cGMP levels as would be expected for a PDE10 inhibitor. The increase in intracellular cGMP levels by ADT 061 was sufficient to activate PKG signaling as evidenced by an increase in VASP phosphorylation at residues known to be phosphorylated by PKG, while the role of cAMP signaling requires further study. The evidence that PDE10 inhibition is responsible for the growth inhibitory activity of ADT 061 agrees with previous studies reporting that genetic knockdown of PDE10 or inhibition of enzymatic activity small molecule inhibitors, such as Pf2545920, can also inhibit colon cancer cell growth (25, 27).

An important distinction between ADT 061 and existing PDE10 inhibitors is that the latter were developed for central nervous system (CNS) disorders such as schizophrenia and Huntington's disease and were designed to cross the blood–brain barrier (41, 42). Pf2545920 and likely other PDE10 inhibitors developed for CNS disorders do not appear to be suitable for cancer indications because of rapid liver metabolism, as well as associated side effects (sedation; refs. 43, 44). ADT 061 did not result in appreciable levels in brain following oral administration and did not cause sedation, but achieved high local concentrations in colon mucosa, likely because of enterohepatic recirculation. These properties of ADT 061, along with its ability to target PDE10 that is overexpressed during early stages of colon tumorigenesis would appear to be consistent with low toxicity as observed in these studies and essential for colorectal cancer chemoprevention.

Mutations in the APC gene, encoding for aberrant adenomatous polyposis coli (APC) protein, occur in over 80% of patients with colorectal cancer and result in loss of tumor suppressor function and activation of Wnt/β-catenin signaling (45). In the absence of Wnt ligand bound to its receptors, β-catenin not bound by cadherin junctions becomes associated with APC, axin, glycogen synthase kinase 3β (GSK3β), and casein kinase 1 (CK1) referred to as the “β-catenin destruction complex,” is degraded by the proteasome (46). CK1 phosphorylation of β-catenin at Ser45 is believed to act as a primer for the phosphorylation by GSK3β at Ser33/37, and Thr41, to induce ubiquitination by β-transducin repeat containing protein (β-TrCP) and proteasomal degradation (47, 48). Wnt binding to Frizzled phosphorylates Dishevelled (Dvl), allowing Dvl to bind axin. Dissociation of the β-catenin destruction complex occurs during colorectal cancer, resulting in the accumulation of β-catenin in the cytoplasm and nuclear translocation, which drives TCF/LEF-mediated transcription of genes encoding for proteins that are essential for proliferation and survival of colon tumor cells (49–53). Individuals with FAP who harbor germline mutations in the APC gene have aberrantly high levels of oncogenic (non-phosphorylated/stabilized) β-catenin, leading to unregulated growth and the formation of adenomas (45, 54). Individuals with sporadic adenomas have similar mutations in APC or β-catenin within dysplastic lesions that give rise to adenomas (55).

PKG activation by ADT 061 was found to counter the effects of mutant APC by reducing β-catenin-dependent TCF/LEF transcriptional activity as shown by a decrease in the phosphorylated (stabilized) form of β-catenin at Ser45 with a corresponding increase in phosphorylation of β-catenin on Ser33/37/Thr41, phosphorylation sites known to induce ubiquitination and degradation (24, 46, 53). ADT 061 treatment of cancer cells also decreased levels of survivin, a protein known to be regulated by TCF/LEF transcription and essential for the proliferation and survival of cancer cells (39), which coincided with increased cleaved caspase 3, a marker of apoptosis. The ability of ADT 061 to block Wnt-induced nuclear localization of β-catenin can be attributed to reduced cytoplasmic levels of β-catenin, resulting from proteasomal degradation. Together, these results show that ADT 061 decreases TCF/LEF transcriptional activity and inhibits colon cancer cell growth by selectively reducing the oncogenic pool of β-catenin leading to induction of apoptosis. These results support previous studies reporting that ectopic expression of PKG can induce apoptosis of colon tumor cells by reducing β-catenin levels (56, 57), as well as reports that PDE10 inhibition by genetic silencing or small molecule inhibitors can suppress β-catenin/TCF-mediated transcriptional activity by activating cGMP/PKG signaling (25). Importantly, we previously published evidence showing that the known PDE10 inhibitor, Pf-2545920, inhibited the growth of colon tumor cell lines through the activation of PKG. However, clinical use of this compound as well as other PDE10 inhibitors developed for CNS diseases is not suitable for colorectal cancer chemoprevention given that such compounds readily cross the blood-brain barrier and cause sedation (27, 41).

The significance of these findings cannot be overstated with respect to the ability of ADT 061 to inhibit PDE10 and activate cGMP/PKG signaling as a novel mechanism for the suppression of the oncogenic pool of β-catenin in cancer cells without affecting normal stem cells that require Wnt/β-catenin signaling for stemness. The lack of effect of ADT 061 on normal stem cell function is supported by experiments showing potent inhibition of colon cancer cell growth expressing PDE10 by ADT 061 without affecting PDE10-null NCM460 cells that were isolated from normal colon mucosa and reported to contain a normal stem cell population (29). Such selectivity may not be shared by other inhibitors of Wnt/β-catenin signaling that presumably failed clinical trials because of toxicities associated with the disruption of normal stem cell function.

Apc+/Min-FCCC mice were used to evaluate the antitumor activity of ADT 061. This spontaneous mouse model of colorectal cancer displays a high incidence and multiplicity of colon adenomas and has been previously used to assess the efficacy of sulindac (32, 58). In addition, tumors and uninvolved colon mucosa from this model express high PDE10 levels relative to normal mucosa from WT mice, findings that agree with previous reports of low PDE10 levels in normal tissues outside of the CNS (59). High levels of PDE10 in dysplastic cells of the colon are consistent with results from other investigators reporting high levels of PDE10 mRNA in adenomas from ApcMin mice (38). In the current study, ADT 061 treatment reduced the multiplicity and incidence of total adenomas (microadenomas, flat, and polypoid adenomas) in a dose-dependent manner. Although treatment with 1,000 ppm ADT 061 decreased colon tumor incidence and multiplicity in Apc+/Min-FCCC mice, the result did not achieve statistical significance. Only the 1,500 ppm dose of ADT 061 inhibited colon tumorigenesis significantly. The lack of toxicity at these doses provides an additional opportunity to explore the antitumor activity of ADT 061 at higher doses.

The greater potency and selectivity of ADT 061 to inhibit PDE10 and cancer cell growth may account for its greater antitumor efficacy in vivo, as compared with sulindac. The ability of sulindac to inhibit intestinal tumors in Apc+/Min-FCCC mice was evaluated in a prior study by this group, using mice that were endoscopically confirmed to be tumor free at the time of study enrollment (same design as the current study; ref. 58). Although administration of sulindac to Apc+/Min-FCCC mice reduced the multiplicity of small intestinal tumors, the incidence and multiplicity of colon tumors in sulindac-treated mice remained comparable with that of untreated controls (58). Other attributes, such as its ability to achieve high local concentrations in colon mucosa as compared with plasma and other tissues following oral administration and lack of COX inhibitory activity may result in low toxicity which is essential for colorectal cancer chemoprevention.

In summary, ADT 061 is a novel non-COX inhibitory derivative of sulindac with PDE10 inhibitory activity that potently and selectively inhibits colon cancer cell growth. The mechanism of action involves competitive inhibition of PDE10 that is overexpressed during early stages of tumorigenesis. The PDE10 inhibitory activity of ADT 061 induced cGMP/PKG signaling to reduce the oncogenic pool of β-catenin driving the transcription of a variety of genes essential for colon cancer cell proliferation and survival. ADT 061 treatment by oral administration achieved high local concentrations in the colon mucosa and significantly inhibited the formation of colon adenomas in Apc+/Min-FCCC mice without discernable toxicity. Although further investigation of efficacy and safety is needed, we conclude that ADT 061 has the potential to prevent or treat adenomas in individuals with FAP or sporadic polyposis at high risk of developing colorectal cancer.

X. Chen reports grants from NCI and other support from ADT Pharmaceutical LLC during the conduct of the study; other support from ADT Pharmaceutical LLC outside the submitted work; in addition, X. Chen has a patent for US Patent App No. 15/537,283) pending. S.J. Leavesley has formed a startup company, SpectraCyte LLC, to commercialize novel spectral imaging technologies that have been developed at the University. However, all of the work performed in this article was performed using a commercially-available Nikon microscope. G. Gorman reports other support from University of South Alabama during the conduct of the study. L. Coward reports other support from University of South Alabama during the conduct of the study. A.B. Keeton reports grants from NCI during the conduct of the study; other support from ADT Pharmaceuticals, LLC outside the submitted work; in addition, A.B. Keeton has a patent for ADT-061 pending. M.L. Clapper reports grants from NIH/NCI during the conduct of the study. G.A. Piazza reports other support from ADT Pharmaceuticals LLC during the conduct of the study; in addition, G.A. Piazza has a patent for U.S. Patent Application No. 15/537,283 pending. No disclosures were reported by the other authors.

K.J. Lee: Conceptualization, data curation, formal analysis, validation, investigation, methodology, writing–original draft, writing–review and editing. W.-C.L. Chang: Resources, data curation, formal analysis, investigation, methodology, writing–review and editing. X. Chen: Data curation, formal analysis, methodology, writing–review and editing. J. Valiyaveettil: Data curation, formal analysis, validation. V. Ramirez-Alcantara: Writing–review and editing. E. Gavin: Data curation, writing–review and editing. A. Musiyenko: Data curation. L. Madeira da Silva: Data curation, formal analysis, writing–review and editing. N.S. Annamdevula: Data curation, formal analysis. S.J. Leavesley: Resources. A. Ward: Data curation. T. Mattox: Writing–review and editing. A.S. Lindsey: Data curation, writing–review and editing. J. Andrews: Resources, software, writing–review and editing. B. Zhu: Writing–review and editing. C. Wood: Data curation. A. Neese: Data curation. A. Nguyen: Data curation. K. Berry: Resources, writing–review and editing. Y. Maxuitenko: Writing–review and editing. M.P. Moyer: Resources. E. Nurmemmedov: Resources, writing–review and editing. G. Gorman: Resources, data curation, formal analysis, writing–review and editing. L. Coward: Data curation, formal analysis, writing–review and editing. G. Zhou: Resources, writing–review and editing. A.B. Keeton: Data curation, writing–review and editing. H.S. Cooper: Resources, formal analysis, writing–review and editing. M.L. Clapper: Resources, formal analysis, writing–review and editing. G.A. Piazza: Conceptualization, resources, supervision, funding acquisition, project administration, writing–review and editing.

The animal work was performed with the technical support of the following core facilities at Fox Chase Cancer Center: Laboratory Animal Facility, Genotyping Components of the Genomics Facility, Small Animal Imaging Component of the Biological Imaging Facility, and the Biostatistics and Bioinformatics Facility.

Funding provided by the NCI, NIH under Award Numbers 1R01CA131378, 1RO1CA148817, 1RO1CA197147, and 1RO1CA155638, to G.A. Piazza and P30 CA006927, to Fox Chase Cancer Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Chan
TA
. 
Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention
.
Lancet Oncol
2002
;
3
:
166
74
.
2.
Gurpinar
E
,
Grizzle
WE
,
Piazza
GA
. 
NSAIDs inhibit tumorigenesis, but how?
Clin Cancer Res
2014
;
20
:
1104
13
.
3.
Alberts
DS
,
Hixson
L
,
Ahnen
D
,
Bogert
C
,
Einspahr
J
,
Paranka
N
, et al
Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
J Cell Biochem Suppl
1995
;
22
:
18
23
.
4.
Piazza
GA
,
Alberts
DS
,
Hixson
LJ
,
Paranka
NS
,
Li
H
,
Finn
T
, et al
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
.
Cancer Res
1997
;
57
:
2909
15
.
5.
Beazer-Barclay
Y
,
Levy
DB
,
Moser
AR
,
Dove
WF
,
Hamilton
SR
,
Vogelstein
B
, et al
SHORT COMMUNICATION: sulindac suppresses tumorigenesis in the Min mouse
.
Carcinogenesis
1996
;
17
:
1757
60
.
6.
Tinsley
HN
,
Gary
BD
,
Thaiparambil
J
,
Li
N
,
Lu
W
,
Li
Y
, et al
Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition
.
Cancer Prev Res
2010
;
3
:
1303
13
.
7.
Giardiello
FM
,
Hamilton
SR
,
Krush
AJ
,
Piantadosi
S
,
Hylind
LM
,
Celano
P
, et al
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
.
N Engl J Med
1993
;
328
:
1313
6
.
8.
Labayle
D
,
Fischer
D
,
Vielh
P
,
Drouhin
F
,
Pariente
A
,
Bories
C
, et al
Sulindac causes regression of rectal polyps in familial adenomatous polyposis
.
Gastroenterology
1991
;
101
:
635
9
.
9.
Nugent
KP
,
Farmer
KCR
,
Spigelman
AD
,
Williams
CB
,
Phillips
RKS
. 
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
.
Br J Surg
1993
;
80
:
1618
9
.
10.
Piazza
GA
,
Rahm
ALK
,
Krutzsch
M
,
Sperl
G
,
Paranka
NS
,
Gross
PH
, et al
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
.
Cancer Res
1995
;
55
:
3110
6
.
11.
Hixson
LJ
,
Alberts
DS
,
Krutzsch
M
,
Einsphar
J
,
Brendel
K
,
Gross
PH
, et al
Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells
.
Cancer Epidemiol Prev Biomark
1994
;
3
:
433
8
.
12.
Duggan
E
,
Hooke
KF
,
Hwang
SS
. 
Kinetics of the tissue distributions of sulindac and metabolites
.
Drug Metab Dispos
1980
;
8
:
241
6
.
13.
Strong
HA
,
Warner
NJ
,
Renwick
AG
,
George
CF
. 
Sulindac metabolism: the importance of an intact colon
.
Clin Pharmacol Ther
1985
;
38
:
387
93
.
14.
Reddy
BS
,
Kawamori
T
,
Lubet
RA
,
Steele
VE
,
Kelloff
GJ
,
Rao
CV
. 
Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
.
Cancer Res
1999
;
59
:
3387
91
.
15.
Charalambous
D
,
O'brien
PE
. 
Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis
.
J Gastroenterol Hepatol
1996
;
11
:
307
10
.
16.
Arber
N
,
Kuwada
S
,
Leshno
M
,
Sjodahl
R
,
Hultcrantz
R
,
Rex
D
. 
Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study
.
Gut
2006
;
55
:
367
73
.
17.
Piazza
GA
,
Thompson
WJ
,
Pamukcu
R
,
Alila
HW
,
Whitehead
CM
,
Liu
L
, et al
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis
.
Cancer Res
2001
;
61
:
3961
8
.
18.
Thompson
WJ
,
Piazza
GA
,
Li
H
,
Liu
L
,
Fetter
J
,
Zhu
B
, et al
Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin
.
Cancer Res
2000
;
60
:
3338
42
.
19.
Stoner
GD
,
Budd
GT
,
Ganapathi
R
,
DeYoung
B
,
Kresty
LA
,
Nitert
M
, et al
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis
.
Adv Exp Med Biol
1999
;
470
:
45
53
.
20.
Piazza
GA
,
Keeton
AB
,
Tinsley
HN
,
Gary
BD
,
Whitt
JD
,
Mathew
B
, et al
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity
.
Cancer Prev Res Phila Pa
2009
;
2
:
572
80
.
21.
Whitt
JD
,
Li
N
,
Tinsley
HN
,
Chen
X
,
Zhang
W
,
Li
Y
, et al
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity
.
Cancer Prev Res
2012
;
5
:
822
33
.
22.
Li
N
,
Chen
X
,
Zhu
B
,
Ramírez-Alcántara
V
,
Canzoneri
JC
,
Lee
K
, et al
Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10
.
Oncotarget
2015
;
6
:
27403
15
.
23.
Bender
AT
,
Beavo
JA
. 
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
.
Pharmacol Rev
2006
;
58
:
488
520
.
24.
Lee
K
,
Piazza
AG
. 
The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer
.
J Biomed Res
2017
;
31
:
189
96
.
25.
Li
N
,
Lee
K
,
Xi
Y
,
Zhu
B
,
Gary
BD
,
Ramírez-Alcántara
V
, et al
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity
.
Oncogene
2015
;
34
:
1499
509
.
26.
Zhu
B
,
Lindsey
A
,
Li
N
,
Lee
K
,
Ramirez-Alcantara
V
,
Canzoneri
JC
, et al
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling
.
Oncotarget
2017
;
8
:
69264
80
.
27.
Lee
K
,
Lindsey
AS
,
Li
N
,
Gary
B
,
Andrews
J
,
Keeton
AB
, et al
β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG
.
Oncotarget
2016
;
7
:
5353
65
.
28.
Sperl
G
,
Gross
P
,
Brendel
K
,
Pamukcu
R
,
Piazza
GA
. 
Substituted benzylidene indenyl formamides, acetamides and propionamides [Internet]
; 
2000
.
Available from:
https://www.freepatentsonline.com/6063818.html.
29.
Moyer
MP
,
Manzano
LA
,
Merriman
RL
,
Stauffer
JS
,
Tanzer
LR
. 
NCM460, a normal human colon mucosal epithelial cell line
.
In Vitro Cell Dev Biol Anim
1996
;
32
:
315
7
.
30.
Annamdevula
N
,
Sweat
B
,
Favreau
P
,
Lindsey
A
,
Alvarez
D
,
Rich
T
, et al
An approach for characterizing and comparing hyperspectral microscopy systems
.
Sensors
2013
;
13
:
9267
93
.
31.
Leavesley
SJ
,
Annamdevula
N
,
Boni
J
,
Stocker
S
,
Grant
K
,
Troyanovsky
B
, et al
Hyperspectral imaging microscopy for identification and quantitative analysis of fluorescently-labeled cells in highly autofluorescent tissue
.
J Biophotonics
2012
;
5
:
67
84
.
32.
Cooper
HS
,
Chang
W-CL
,
Coudry
R
,
Gary
MA
,
Everley
L
,
Spittle
CS
, et al
Generation of a unique strain of multiple intestinal neoplasia (Apc+/Min-FCCC) mice with significantly increased numbers of colorectal adenomas
.
Mol Carcinog
2005
;
44
:
31
41
.
33.
Hensley
HH
,
Merkel
CE
,
Chang
W-CL
,
Devarajan
K
,
Cooper
HS
,
Clapper
ML
. 
Endoscopic imaging and size estimation of colorectal adenomas in the multiple intestinal neoplasia mouse
.
Gastrointest Endosc
2009
;
69
:
742
9
.
34.
Boivin
GP
,
Washington
K
,
Yang
K
,
Ward
JM
,
Pretlow
TP
,
Russell
R
, et al
Pathology of mouse models of intestinal cancer: consensus report and recommendations
.
Gastroenterology
2003
;
124
:
762
77
.
35.
Deguchi
A
,
Soh
J-W
,
Li
H
,
Pamukcu
R
,
Thompson
WJ
,
Weinstein
IB
. 
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G
.
Mol Cancer Ther
2002
;
1
:
803
9
.
36.
Li
N
,
Xi
Y
,
Tinsley
HN
,
Gurpinar
E
,
Gary
BD
,
Zhu
B
, et al
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling
.
Mol Cancer Ther
2013
;
12
:
1848
59
.
37.
Giralt
A
,
Saavedra
A
,
Carretón
O
,
Arumí
H
,
Tyebji
S
,
Alberch
J
, et al
PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model
.
Hippocampus
2013
;
23
:
684
95
.
38.
Sharman
SK
,
Islam
BN
,
Hou
Y
,
Singh
N
,
Berger
FG
,
Sridhar
S
, et al
Cyclic-GMP-elevating agents suppress polyposis in ApcMin mice by targeting the preneoplastic epithelium
.
Cancer Prev Res
2018
;
11
:
81
92
.
39.
Torres
VA
,
Tapia
JC
,
Rodriguez
DA
,
Lladser
A
,
Arredondo
C
,
Leyton
L
, et al
E-Cadherin is required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via reduced β-catenin-Tcf/Lef-dependent transcription
.
Mol Cell Biol
2007
;
27
:
7703
17
.
40.
Tinsley
HN
,
Gary
BD
,
Keeton
AB
,
Lu
W
,
Li
Y
,
Piazza
GA
. 
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin–mediated transcription in human breast tumor cells
.
Cancer Prev Res
2011
;
4
:
1275
84
.
41.
Delnomdedieu
M
,
Forsberg
A
,
Ogden
A
,
Fazio
P
,
Yu
C-R
,
Stenkrona
P
, et al
In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects
.
Neuropharmacology
2017
;
117
:
171
81
.
42.
Verhoest
PR
,
Chapin
DS
,
Corman
M
,
Fonseca
K
,
Harms
JF
,
Hou
X
, et al
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia
.
J Med Chem
2009
;
52
:
5188
96
.
43.
DeMartinis
NI
,
Lopez
RN
,
Pickering
EH
,
Schmidt
CJ
,
Gertsik
L
,
Walling
DP
, et al
A proof-of-concept study evaluating the phosphodiesterase 10A inhibitor PF-02545920 in the adjunctive treatment of suboptimally controlled symptoms of schizophrenia
.
J Clin Psychopharmacol
2019
;
39
:
318
28
.
44.
Walling
DP
,
Banerjee
A
,
Dawra
V
,
Boyer
S
,
Schmidt
CJ
,
DeMartinis
N
. 
Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia
.
J Clin Psychopharmacol
2019
;
39
:
575
82
.
45.
Kinzler
KW
,
Vogelstein
B
. 
Lessons from hereditary colorectal cancer
.
Cell
1996
;
87
:
159
70
.
46.
Stamos
JL
,
Weis
WI
. 
The β-catenin destruction complex
.
Cold Spring Harb Perspect Biol
2013
;
5
:
a007898
.
47.
Yost
C
,
Torres
M
,
Miller
JR
,
Huang
E
,
Kimelman
D
,
Moon
RT
. 
The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3
.
Genes Dev
1996
;
10
:
1443
54
.
48.
Winston
JT
,
Strack
P
,
Beer-Romero
P
,
Chu
CY
,
Elledge
SJ
,
Harper
JW
. 
The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro
.
Genes Dev
1999
;
13
:
270
83
.
49.
Clevers
H
,
Nusse
R
. 
Wnt/β-catenin signaling and disease
.
Cell
2012
;
149
:
1192
205
.
50.
Giles
RH
,
van Es
JH
,
Clevers
H
. 
Caught up in a Wnt storm: Wnt signaling in cancer
.
Biochim Biophys Acta
2003
;
1653
:
1
24
.
51.
He
T-C
,
Sparks
AB
,
Rago
C
,
Hermeking
H
,
Zawel
L
,
da Costa
LT
, et al
Identification of c-MYC as a target of the APC pathway
.
Science
1998
;
281
:
1509
12
.
52.
Shtutman
M
,
Zhurinsky
J
,
Simcha
I
,
Albanese
C
,
D'Amico
M
,
Pestell
R
, et al
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
.
Proc Natl Acad Sci U S A
1999
;
96
:
5522
7
.
53.
Kolligs
FT
,
Bommer
G
,
Göke
B
. 
Wnt/Beta-catenin/Tcf signaling: a critical pathway in gastrointestinal tumorigenesis
.
Digestion
2002
;
66
:
131
44
.
54.
Groden
J
,
Thliveris
A
,
Samowitz
W
,
Carlson
M
,
Gelbert
L
,
Albertsen
H
, et al
Identification and characterization of the familial adenomatous polyposis coli gene
.
Cell
1991
;
66
:
589
600
.
55.
Yamagishi
H
,
Kuroda
H
,
Imai
Y
,
Hiraishi
H
. 
Molecular pathogenesis of sporadic colorectal cancers
.
Chin J Cancer
2016
;
35
:
4
.
56.
Deguchi
A
,
Thompson
WJ
,
Weinstein
IB
. 
Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells
.
Cancer Res
2004
;
64
:
3966
73
.
57.
Liu
L
,
Underwood
T
,
Li
H
,
Pamukcu
R
,
Thompson
WJ
. 
Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase
.
Cell Signal
2002
;
14
:
45
51
.
58.
Chang
W-CL
,
Jackson
C
,
Riel
S
,
Cooper
HS
,
Devarajan
K
,
Hensley
HH
, et al
Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas
.
Gut
2018
;
67
:
1290
8
.
59.
Coskran
TM
,
Morton
D
,
Menniti
FS
,
Adamowicz
WO
,
Kleiman
RJ
,
Ryan
AM
, et al
Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species
.
J Histochem Cytochem
2006
;
54
:
1205
13
.

Supplementary data